Webb G, Baker M S, Nicholl J, Wang Y, Woodrow G, Kruithof E, Doe W F
Division of Clinical Sciences, John Curtin School of Medical Research, Australian National University, Canberra.
J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):340-3. doi: 10.1111/j.1440-1746.1994.tb01252.x.
Activation of the proenzyme of urokinase (uPA) on the surface of cancer cells has been implicated in the initiation of focal proteolytic mechanisms that permit invasion and metastasis by colon cancers. The activity of uPA on the cell surface appears to be a function of the number of uPA-specific receptors (uPAR) and the extent of inhibition of uPA by plasminogen activator inhibitors (PAI). The mapping of the genes coding for uPAR, and for PAI-2, was performed to determine whether their chromosomal localization suggested their involvement in the genetic alterations associated with cancer cell DNA. This study confirms the localization of the human urokinase plasminogen activator receptor gene to chromosome 19q and, using in situ hybridization, provides a precise localization to chromosome 19q13.2. In addition, our results confirm the previous allocation of the human plasminogen activator inhibitor-2 gene to a location 18q21.3-->18q22.1, a location that corresponds to the commonest (> 70%) somatic deletions found in colorectal carcinomas. The mapping of the uPAR and PAI-2 genes enables the elucidation of their possible involvement in the genetic alterations that determine the invasive and metastatic phenotypes in colorectal cancer.
尿激酶(uPA)酶原在癌细胞表面的激活与局部蛋白水解机制的启动有关,该机制使得结肠癌能够发生侵袭和转移。uPA在细胞表面的活性似乎取决于uPA特异性受体(uPAR)的数量以及纤溶酶原激活物抑制剂(PAI)对uPA的抑制程度。对编码uPAR和PAI-2的基因进行定位,以确定它们的染色体定位是否表明它们参与了与癌细胞DNA相关的基因改变。本研究证实了人尿激酶纤溶酶原激活物受体基因定位于19号染色体q臂,并且通过原位杂交,将其精确定位于19q13.2。此外,我们的结果证实了前人将人纤溶酶原激活物抑制剂-2基因定位于18q21.3→18q22.1的结果,该位置对应于在结肠直肠癌中发现的最常见(>70%)的体细胞缺失区域。uPAR和PAI-2基因的定位有助于阐明它们可能参与决定结肠直肠癌侵袭和转移表型的基因改变。